INTERIM RESULTS AS OF MARCH 31, 2016



CSE/OMX:BAVA, OTC:BVNRY

FORWARD-LOOKING STATEMENTS

This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements regarding our short-term objectives and opportunities, financial expectations for the full year and financial preparedness as of year end, as well as statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

FIRST QUARTER 2016 HIGHLIGHTS

- DKK 665 (~\$100) million raised in successful private placement backed by international institutional investors
- Ebola Phase 1 results published in JAMA showed that the prime-boost vaccine regimen produced an antibody response in 100 percent of healthy volunteers that was sustained 8 months indicating potential for a durable response
- Interim analysis #1 of PROSTVAC Phase 3 confirmed that the study continue without modification
- Two new Phase 2 clinical studies of PROSTVAC initiated by the NCI
- End of Phase 2 meeting with the FDA for IMVAMUNE concluded that immunogenicity could be bridged between the two formulations and that the proposed single Phase 3 lot consistency study is sufficient for approval of freeze-dried IMVAMUNE

FINANCIALS



Q1 revenues as expected

- More than 90% of revenues will be recognized in 2H 2016
- FY revenue and results expectations maintained
- Cash preparedness upgraded after successful capital increase in April
 - 2.77 million new shares sold, yielding DKK 665 (~\$100) million in gross proceeds


	DKK million			USD million			
	3m 2013	3m 2015	FY2016E	3m 2016	3m 2015	FY2016E	
Revenue	23	235	1,000	4	36	153	
EBIT	(153)	(40)	0	(23)	(6)	0	
Cash preparedness	1,365	1,619	1,900	209	248	291	

Main assumptions for FY2016E: Revenue of DKK 750 million from IMVAMUNE sales and DKK 250 million from R&D contracts. Total R&D costs of DKK 580 million, which include DKK 110 million in contract expenses (stated under production costs in the P&L statement) as well as DKK 25 million capitalized in the balance sheet. Cash preparedness includes cash, cash equivalents, investments in securities and the aggregate amount of undrawn credit lines.

USD/DKK = 6.54 (as of March 31, 2016)

All numbers are approximate.

FINANCIAL STATEMENTS




STRONG FOUNDATION FOR FURTHER DEVELOPMENT


PROSTVAC	prostate cancer	IMVAMUNE	smallpox vaccine			
Partnered with	Bristol-Myers Squibb	Approved in EU & Canada				
• Phase 3 fully en	rolled	 28 million doses delivered to US 				
Multiple clinical	e data expected in 2017 studies being advanced and in combination	 USD 133 million bulk vaccine order bridging to next-generation freeze-dried vaccine Recurrent orders from Canada 				
		 Pipeline projects Advancing clinical development of RSV vaccine in elderly & children Advancing development of CV-301 in combination treatment for multiple cancers Supporting NCI in clinical development of MVA-BN Brachyury 				

IMVAMUNE PARTNERSHIP WITH THE U.S.

Long-term stockpiling goal



OUR COLLABORATION WITH JANSSEN





A sustained partnership

- Janssen took almost 5% equity stake in BN upon signing Ebola deal
- Validation of our MVA-BN technology & manufacturing
- Recent publication of Ebola Phase 1 data confirms durable immune responses when combining MVA-BN and AdVac.

EMERGING THREATS AND TROPICAL DISEASES

- At the request of certain health authorities, including WHO and BARDA, the Company has submitted separate proposals to each group
- These proposals outline potential ways MVA could be utilized in the fight against emerging threats including tropical diseases such as Zika Virus

BN would only pursue this strategy with the backing and funding of interested parties. i.e. Governments or global agencies.

MVA-BN AS A PLATFORM: A MODEL FOR PREPAREDNESS



MVA Platform- Exploratory

- Develop and investigate countermeasures against various emerging and tropical diseases.
- Ex: Zika, Chikungunya, etc.
- Conduct proof of concept "animal rule" studies


PREPAREDNESS



Phase 1:

- Human safety and immunogenicity data
- Process validation
- Projects are placed at the ready for potential outbreaks

EPIDEMIC LEVEL



Emergency or Outbreak

- Immediately scale up production
- Conduct additional clinical studies, as needed.
- Deployment and/or Stockpiling

RESPONSE




Large unmet medical need: children & elderly

- Global RSV disease burden is estimated at 64 million cases and 160,000 deaths every year
- The U.S. Centers for Disease Control and Prevention (CDC) reports that each year the disease causes 177,000 hospitalizations and 14,000 deaths among adults older than 65
- No approved prophylactic vaccine available




MVA-BN RSV IS IMMUNOGENIC & EFFICACIOUS IN COTTON RATS

Neutralizing Antibodies @ A & B Strain



RSV Clearance from the lung



- 2nd study confirmed the promising results that MVA-BN *RSV* was equally immunogenic and efficacious as a natural RSV infection (+ve control).
- A 3rd study is being planned to investigate MVA-BN *RSV* given i.n. in cotton rats


PROSTVAC CANCER IMMUNOTHERAPY PHASE 3 STUDY STATUS



PROSPECT

A Randomized, Double-blind, Global Phase 3 Efficacy Trial of PROSTVAC in Metastatic Castration-Resistant Prostate Cancer

Randomization by region (N=1,297)



Final data anticipated in 2017

Interim Analysis #1	\checkmark	214 events	40%
Interim Analysis #2		321 events	60%
Interim Analysis #3		427 events	80%
Final Analysis		534 events	100%


Injections

- Average was 6.1 injections¹
- Randomized Phase 2 trial (n=122) had average of 5.4 injections²
- An increased number of injections is expected to improve the clinical outcome for patients receiving the active drug.


1) Subjects who have completed study treatment phase or have completed $7^{\rm th}$ dosing visit. N=1,279

2) Kantoff et al., Journal of Clinical Oncology, January 2010

ONGOING PROSTVAC STUDIES SPAN PROSTATE CANCER DISEASE LANDSCAPE



New and improved vaccine construct based on MVA-BN




Leverage Existing Clinical Data

Preliminary evidence of efficacy generated in multiple clinical studies.

Safety data with over 300 subjects treated.

CV-301 in Combination with Immune Checkpoint Inhibitors



PIPELINE



PRODUCT	INDICATION	ONGOING STUDIES	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	MARKET	PARTNER
INFECTIOUS DISEASES								
IMVAMUNE liquid-frozen ¹⁾	Smallpox	1						BARDA
IMVAMUNE freeze-dried	Smallpox	-						BARDA
MVA-BN Filo	Ebola/Marburg	9						Janssen
MVA-BN RSV	RSV	1						
MVA-BN HPV	Chronic HPV Infection	-						Janssen
CANCER IMMUNOTHERAPY								
PROSTVAC	Prostate Cancer	8						Bristol-Myers Squibb
CV-301	Bladder Cancer	1						NCI
MVA-BN Brachyury	Metastatic Tumors	1						NCI

1) Approved in the European Union under the trade name IMVANEX[®] and in Canada under the trade name IMVAMUNE[®]. Phase 3 registration studies are ongoing in the United States.

ANTICIPATED SELECTED MILESTONES 2016/2017



PROSTVAC	prostate cancer	IMVAMUNE	smallpox vaccine			
 Phase 3 top-line data including interim analyses Data from NCI-sponsored Phase 2 trials Initiate Phase 2 study in combination with ipilimumab in collaboration with BMS Initiate NCI-sponsored Phase 2 study in combination with ipilimumab and nivolumab 		 Finalize manufacturing activities to support a U.S. EUA for freeze-dried IMVAMUNE Additional Rest of World orders Complete enrolment of Phase 3 non-inferiority study 				
Ebola prime-boostInitiate HPV PhasePotential expande	 Janssen partnership Complete Phase 2 and Phase 3 studies of the Ebola prime-boost vaccine regimen Initiate HPV Phase 1 study in cervical cancer Potential expanded collaboration with Janssen on two additional infectious disease targets 		 Pipeline projects MVA-BN RSV Phase 1 data MVA-BN RSV Phase 2 dosing study initiation + read out MVA-BN RSV Phase 2 field efficacy initiation MVA-BN RSV Phase 1 pediatric study initiation MVA-BN Brachyury Phase 2 initiation CV-301 + nivo Phase 2 initiation in lung cancer CV-301 + checkpoint inhibitor Phase 2 initiation in two additional indications 			



